Quarterly paliperidone injection for patients with schizophrenia

Trevicta (paliperidone palmitate) is a 3-monthly sustained-release injection for the maintenance treatment of schizophrenia. It can be given once patients are clinically stable on monthly paliperidone palmitate injection (Xeplion).

The extended dosing interval of Trevicta may help to reduce the risk of relapse caused by poor adherence to treatment.

Further information
View Trevicta drug record
Summary of Product Characteristics
Manufacturer: Janssen-Cilag

Trevicta is administered by intramuscular injection into the deltoid or gluteal muscle, with dose adjustments when required within the range of 175mg to 525mg.

Similar to other antipsychotics, the most common adverse effects experienced by patients given the quarterly paliperidone palmitate injection included insomnia, extrapyramidal effects, weight change, hyperglycaemia, urinary tract infection, upper respiratory tract infection and headache.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Prescribers alerted to topical steroid withdrawal reactions

Prescribers alerted to topical steroid withdrawal reactions

The MHRA has issued advice for prescribers to minimise...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...